Question special

In comparing these two critical trials in hindsight, the rates of superinfection and GI bleed appeared to be similar to placebo regardless which strategy—continuous infusion or bolus—was used (see ADRENAL Table 2 and APROCCHSS Table S12). There was significantly more hyperglycemia in the HC + FC group than placebo in APROCCHSS. By comparison, hyperglycemia as reported as an adverse event was rare with HC in the ADRENAL Trial, but we don't know the statistical significance of this as compared to placebo.